Opportunity Information: Apply for RFA AI 12 033
Apply for RFA AI 12 033
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co morbidities (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Jun 22, 2012 and posted on Jun 13, 2012.
- Applicants must submit their applications by Sep 4, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Special district governments County governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Private institutions of higher education City or township governments State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-morbidities (R21) opportunity (Funding Opportunity Number RFA-AI-12-033) is a National Institutes of Health (NIH) grant program meant to spark new or early-stage research collaborations between U.S. institutions and partner institutions in India. It uses the NIH Exploratory/Developmental Research Grant mechanism (R21), which is typically suited for pilot studies, proof-of-concept work, and generating preliminary data rather than running large, definitive trials right away. The central idea is to help U.S. and Indian investigators combine their expertise and institutional strengths to move HIV prevention science forward in ways that matter to both countries, while also laying the groundwork for longer-term partnerships and larger future proposals.
The scientific scope is focused on HIV/AIDS prevention and on HIV-associated co-morbidities that complicate prevention and long-term outcomes. In addition to prevention research directly aimed at reducing HIV transmission or acquisition risk, the announcement explicitly calls out co-morbidities such as malignancies, metabolic complications, and opportunistic infections (OIs). In practice, that framing supports projects that either prevent these HIV-related complications, improve their treatment, or reduce their severity (ameliorate them), especially where doing so ties back to prevention goals, health outcomes, and implementation realities in U.S. and Indian settings. The program is designed to leverage the research capacities in both countries, meaning proposals should reflect true collaboration and shared scientific value, not a one-sided arrangement.
From a funding and project-size standpoint, the FOA lists an estimated total funding amount of $3,000,000 and an award ceiling of $200,000. Because this is an R21 announcement, it is geared toward smaller, targeted studies that can produce the kind of early evidence needed to justify a more extensive follow-on study, such as a larger intervention trial or a broader implementation or effectiveness project to test an HIV prevention program. The announcement also specifies that there is no cost sharing or matching requirement, which reduces barriers for applicants that might otherwise struggle to provide non-federal funds.
Eligibility is broad on the U.S. side and includes many common applicant types such as public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), for-profit organizations (other than small businesses are explicitly listed, though small businesses are also eligible), and a wide range of government entities (state, county, city/township, special district governments, independent school districts, public housing authorities, and tribal governments). The eligibility section also highlights categories often emphasized in federal programs, including Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and eligible federal agencies. A key restriction is that non-U.S. entities (foreign institutions) are not eligible to apply as the applicant organization, and non-U.S. components of U.S. organizations are also not eligible to apply. However, the FOA notes that foreign components (as defined by the NIH Grants Policy Statement) are allowed, which is relevant because the model requires a substantive partnership with an Indian institution even though the applicant organization must be U.S.-based.
Administratively, this is a discretionary grant opportunity with a posted date of June 13, 2012, and key dates showing an original and current closing date of September 4, 2012, with an archive date of October 5, 2012. Those dates indicate this particular announcement is historical (archived), but the summary still reflects how NIH framed the program: develop bilateral, collaborative HIV prevention research that is mutually beneficial, produce preliminary data, and create a platform for more ambitious future work. The NIH listing also provides a link to the full FOA text and directs technical access questions to the NIH Office of Extramural Research (OER) webmaster, which is typical for NIH announcements.
Overall, the grant opportunity is best understood as a pilot-funding mechanism to seed U.S.-India research teams working on HIV prevention and HIV-related co-morbidities, with an emphasis on collaboration, feasibility, early evidence generation, and positioning teams for larger subsequent studies that can more rigorously test prevention programs or strategies in real-world contexts.
Frequently Asked Questions (FAQs)
What is the U.S.-India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-morbidities (R21)?
This opportunity is an NIH grant program designed to spark new or early-stage research collaborations between U.S. institutions and partner institutions in India. It uses the NIH Exploratory/Developmental Research Grant mechanism (R21), which is generally intended for pilot studies, proof-of-concept projects, and preliminary data generation rather than large, definitive trials.
What is the Funding Opportunity Number (FOA number) for this grant?
The Funding Opportunity Number is RFA-AI-12-033.
What is the main purpose of this funding opportunity?
The main purpose is to help U.S. and Indian investigators combine expertise and institutional strengths to advance HIV prevention science in ways that matter to both countries, while laying the groundwork for longer-term partnerships and larger future proposals.
What grant mechanism does this program use, and what does it imply about project type?
The program uses the NIH R21 mechanism (Exploratory/Developmental Research Grant). This implies the projects are expected to be smaller and targeted, suitable for feasibility work, pilot testing, and generating early evidence that could justify a larger follow-on study later.
What scientific topics are within the scope of this opportunity?
The scientific scope focuses on HIV/AIDS prevention and HIV-associated co-morbidities that complicate prevention and long-term outcomes. In addition to prevention research aimed at reducing HIV transmission or acquisition risk, the opportunity explicitly calls out co-morbidities such as malignancies, metabolic complications, and opportunistic infections (OIs).
Does the opportunity cover work on HIV-related co-morbidities, or only prevention?
It covers both. The opportunity includes HIV prevention research and also HIV-associated co-morbidities, including malignancies, metabolic complications, and opportunistic infections (OIs). Projects may focus on preventing these complications, improving their treatment, or reducing their severity (ameliorating them), particularly where this connects back to prevention goals and health outcomes.
What kinds of outcomes or project aims fit the intent of this FOA?
Projects that generate preliminary data, demonstrate feasibility, or provide proof-of-concept evidence aligned with HIV prevention and HIV-related co-morbidities fit the intent. The FOA emphasizes positioning teams for larger subsequent studies, such as a larger intervention trial or a broader implementation/effectiveness project to test an HIV prevention program.
Is this opportunity meant for large clinical trials?
The R21 mechanism is typically used for smaller exploratory or developmental studies rather than large, definitive trials. The described purpose is to support early evidence generation and feasibility work that could later lead to more extensive studies.
How important is the U.S.-India collaboration component?
It is central to the opportunity. Proposals are expected to reflect true bilateral collaboration and shared scientific value, leveraging research capacities in both countries rather than operating as a one-sided arrangement.
What is the estimated total funding amount for this FOA?
The FOA lists an estimated total funding amount of $3,000,000.
What is the award ceiling (maximum award amount) mentioned in the FOA?
The FOA lists an award ceiling of $200,000.
Is there a cost sharing or matching requirement?
No. The announcement specifies there is no cost sharing or matching requirement.
Who is eligible to apply as the applicant organization?
Eligibility on the U.S. side is broad and includes public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), for-profit organizations (with small businesses also eligible), and a wide range of government entities (state, county, city/township, special district governments, independent school districts, public housing authorities, and tribal governments).
Are minority-serving institutions and community organizations included in the eligibility description?
Yes. The eligibility section highlights categories such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and eligible federal agencies.
Can a non-U.S. (foreign) institution apply as the main applicant?
No. A key restriction is that non-U.S. entities (foreign institutions) are not eligible to apply as the applicant organization.
Can non-U.S. components of U.S. organizations apply as the applicant organization?
No. The FOA states that non-U.S. components of U.S. organizations are also not eligible to apply.
Are foreign components allowed at all under this opportunity?
Yes. The FOA notes that foreign components (as defined by the NIH Grants Policy Statement) are allowed, which is relevant because the model requires a substantive partnership with an Indian institution even though the applicant organization must be U.S.-based.
Does this opportunity require a partnership with an institution in India?
It is described as a bilateral collaborative partnership opportunity intended to bring together U.S. institutions and partner institutions in India. The program description emphasizes substantive collaboration with an Indian institution as part of the model.
What type of grant is this, administratively?
It is described as a discretionary grant opportunity.
What are the key dates listed for this FOA?
The posted date is June 13, 2012. The original and current closing date is September 4, 2012. The archive date is October 5, 2012.
Is this funding opportunity current or historical?
The dates show it was archived (archive date: October 5, 2012), which indicates this specific FOA is historical rather than currently open.
Where does NIH typically direct technical access questions for listings like this?
The NIH listing directs technical access questions to the NIH Office of Extramural Research (OER) webmaster.
What is the overall “best fit†use of this opportunity based on the description?
It is best understood as pilot funding to seed U.S.-India research teams working on HIV prevention and HIV-related co-morbidities, emphasizing collaboration, feasibility, and early evidence generation to position teams for larger subsequent studies.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Health and Humanitarian Assistance Service Delivery Grants
Previous opportunity: Research Resource for Human Organs and Tissues (U42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 12 033
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 12 033) also looked into and applied for these:
| Funding Opportunity |
|---|
| Establish Sharing of Human Brain Image Data Relevant to Drug Addiction (Admin Supp) Apply for PAR 12 204 Funding Number: PAR 12 204 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 13 008 Funding Number: RFA DA 13 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R01) Apply for PA 12 213 Funding Number: PA 12 213 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PAR 12 239 Funding Number: PAR 12 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24) Apply for RFA CA 12 014 Funding Number: RFA CA 12 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10) Apply for RFA CA 12 504 Funding Number: RFA CA 12 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 12 033", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.